16. Crow-Fukase syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 13 / Drugs : 14 - (DrugBank : 7) / Drug target genes : 4 - Drug target pathways : 75
Crow-Fukase syndrome and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
ID | Diseases (Sorted by score) | Score |
---|---|---|
16 | Crow-Fukase syndrome | - |
49 | Systemic lupus erythematosus | 5.000 |
28 | Systemic amyloidosis | 5.000 |
331 | Idiopathic multicentric castleman disease | 3.303 |
26 | HTLV-1-associated myelopathy | 3.284 |
51 | Scleroderma | 3.228 |
46 | Malignant rheumatoid arthritis | 3.217 |
13 | Multiple sclerosis/Neuromyelitis optica | 3.212 |
38 | Stevens-Johnson syndrome | 2.040 |
45 | Eosinophilic granulomatosis with Polyangiitis | 2.000 |
283 | Acquired pure red cell aplasia | 2.000 |
284 | Diamond-Blackfan anemia | 1.964 |
35 | Pemphigus | 1.964 |
40 | Takayasu arteritis | 1.944 |
61 | Autoimmune hemolytic anemia | 1.944 |
42 | Polyarteritis nodosa | 1.938 |
285 | Fanconi anemia | 1.920 |
41 | Giant cell arteritis | 1.909 |
228 | Bronchiolitis obliterans | 1.909 |
164 | Oculocutaneous albinism | 1.906 |
66 | IgA nephropathy | 1.903 |
60 | Aplastic anemia | 1.886 |
11 | Myasthenia gravis | 1.880 |
63 | Idiopathic thrombocytopenic purpura | 1.880 |
222 | Primary nephrotic syndrome | 1.859 |
19 | Lysosomal storage disease | 1.852 |
65 | Primary immunodeficiency | 1.840 |
85 | Idiopathic interstitial pneumonia | 1.836 |
96 | Crohn disease | 1.821 |
2 | Amyotrophic lateral sclerosis | 1.821 |
25 | Progressive multifocal leukoencephalopathy | 1.143 |
39 | Toxic epidermal necrolysis | 1.018 |
220 | Rapidly progressive glomerulonephritis | 1.000 |
30 | Distal myopathy | 1.000 |